Recent advances in applying nanotechnologies for cancer immunotherapy

Cancer immunotherapy aimed at boosting cancer-specific immunoresponses to eradicate tumor cells has evolved as a new treatment modality. Nanoparticles incorporating antigens and immunomodulatory agents can activate immune cells and modulate the tumor microenvironment to enhance anti-tumor immunity....

Full description

Saved in:
Bibliographic Details
Published in:Journal of controlled release 2018-10, Vol.288, p.239-263
Main Authors: Mahjub, Reza, Jatana, Sukhdeep, Lee, Suen Ern, Qin, Zhu, Pauli, Griffin, Soleimani, Meysam, Madadi, Soheil, Li, Shyh-Dar
Format: Article
Language:English
Subjects:
Antigenic pDNA
Antigenic Peptides
Cancer Immunotherapy
Immune check point inhibitor
Immunomodulatory siRNA
Nanoparticles
Oligodeoxynucleotides
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cancer immunotherapy aimed at boosting cancer-specific immunoresponses to eradicate tumor cells has evolved as a new treatment modality. Nanoparticles incorporating antigens and immunomodulatory agents can activate immune cells and modulate the tumor microenvironment to enhance anti-tumor immunity. The nanotechnology approach has been demonstrated to be superior to standard formulations in in-vivo settings. In this article, we focus on recent advances made within the last 5 years in nanoparticle-based cancer immunotherapy, including peptide- and nucleic acid-based nanovaccines, nanomedicines containing an immunoadjuvant to activate anti-tumor immunity, nanoparticle delivery of immune checkpoint inhibitors and the combination of the above approaches. Encouraging results and new emerging nanotechnologies in drug delivery promise the continuous growth of this field and ultimately clinical translation of enhanced immunotherapy of cancer. The schematic illustration of various nanoparticle delivery systems for cancer immunotherapy. [Display omitted]
ISSN:0168-3659
1873-4995
DOI:10.1016/j.jconrel.2018.09.010